Inspire Veterinary Partners Enters Material Definitive Agreement
Ticker: IVPR · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1939365
| Field | Detail |
|---|---|
| Company | Inspire Veterinary Partners, Inc. (IVPR) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $25,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Inspire Vet Partners signed a big deal, filing shows. Details to come.
AI Summary
Inspire Veterinary Partners, Inc. announced on December 20, 2024, that it entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Nevada and its principal executive offices are located in Virginia Beach, VA.
Why It Matters
This filing indicates a significant new agreement for Inspire Veterinary Partners, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The nature of the 'Material Definitive Agreement' is not specified, introducing uncertainty about its impact.
Key Players & Entities
- INSPIRE VETERINARY PARTNERS, INC. (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 780 Lynnhaven Parkway , Suite 400 Virginia Beach , VA 23452 (address) — Address of principal executive offices
- ( 757 ) 734-5464 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on December 20, 2024.
When was the earliest event reported in this filing?
The earliest event reported was on December 20, 2024.
In which state is Inspire Veterinary Partners, Inc. incorporated?
Inspire Veterinary Partners, Inc. is incorporated in Nevada.
What is the company's principal executive office address?
The principal executive offices are located at 780 Lynnhaven Parkway, Suite 400, Virginia Beach, VA 23452.
What is the registrant's telephone number?
The registrant's telephone number is (757) 734-5464.
Filing Stats: 988 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-12-31 19:37:27
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 IVP Nasdaq Capital Market Indicat
- $25,000,000 — , for aggregate gross proceeds of up to $25,000,000 (the "Shares"). The offer and sale of t
Filing Documents
- ea0226548-8k_inspire.htm (8-K) — 31KB
- ea022654801ex1-1_inspire.htm (EX-1.1) — 210KB
- ea022654801ex5-1_inspire.htm (EX-5.1) — 8KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-114196.txt ( ) — 482KB
- ivp-20241220.xsd (EX-101.SCH) — 3KB
- ivp-20241220_lab.xml (EX-101.LAB) — 33KB
- ivp-20241220_pre.xml (EX-101.PRE) — 22KB
- ea0226548-8k_inspire_htm.xml (XML) — 4KB
01 Entry Into
Item 1.01 Entry Into a Material Definitive Agreement. On December 20, 2024, Inspire Veterinary Partners, Inc. a Nevada corporation (the "Company") entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC, as sales agent ("Wainwright"), pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company's common stock, par value $0.0001 per share, for aggregate gross proceeds of up to $25,000,000 (the "Shares"). The offer and sale of the Shares will be made pursuant to a previously shelf registration statement on Form S-3 (File No. 333- 282355) and the related prospectus, as supplemented by a prospectus supplement dated December 20, 2024 (the "Registration Statement") and filed with the Securities and Exchange Commission on such date pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act"). The Company intends to use the net proceeds from the offering, if any, for working capital and general corporate purposes and to repay certain indebtedness. Pursuant to the ATM Agreement, Wainwright may sell the Shares in sales deemed to be "at-the-market" equity offerings as defined in Rule 415 promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market. If agreed to in a separate terms agreement, the Company may sell Shares to Wainwright as principal, at a purchase price agreed upon by Wainwright and the Company. Wainwright may also sell Shares in negotiated transactions with the Company's prior approval. The offer and sale of the Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the issuance and sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Wainwright or the Company pursuant to the terms thereof. The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Agreement or terminate the Ag
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 At The Market Agreement, dated December 20, 2024, by and between Inspire Veterinary Partners, Inc. and H.C. Wainwright & Co., LLC 5.1 Opinion of The Crone Law Group, P.C. 23.1 Consent of The Crone Law Group, P.C. (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 30, 2024 INSPIRE VETERINARY PARTNERS, INC. By: /s/ Kimball Carr Name: Kimball Carr Title: President and Chief Executive Officer 2